JCLA:ANGPTL2基因启动子甲基化与冠心病关系的初步研究

2019-07-15 不详 网络

冠心病主要由冠状动脉粥样硬化引起。它主要是一种血管壁炎症性疾病。炎症与DNA甲基化有关。血管生成素‐类蛋白2 (ANGPTL2)在多种慢性炎症疾病中具有多种功能。巨噬细胞来源的ANGPTL2被报道可加速冠心病的发展。据报道,ANGPTL2基因启动子区DNA低甲基化与急性冠状动脉综合征(ACS)有关。目的探讨ANGPTL2基因启动子甲基化与冠心病的关系,探讨甲基化状态与冠心病患者临床特征的关系。

冠心病主要由冠状动脉粥样硬化引起。它主要是一种血管壁炎症性疾病。炎症与DNA甲基化有关。血管生成素‐类蛋白2 (ANGPTL2)在多种慢性炎症疾病中具有多种功能。巨噬细胞来源的ANGPTL2被报道可加速冠心病的发展。据报道,ANGPTL2基因启动子区DNA低甲基化与急性冠状动脉综合征(ACS)有关。目的探讨ANGPTL2基因启动子甲基化与冠心病的关系,探讨甲基化状态与冠心病患者临床特征的关系。

首先,我们从汉族人群中收集122例冠心病患者和58例非冠心病患者的外周血DNA进行纯化。对纯化的DNA进行亚硫酸氢盐修饰。亚硫酸氢盐转化后,用聚合酶链反应(PCR)扩增目标DNA位点,用焦磷酸测序法测定PCR产物。最后根据测序结果计算甲基化水平,并使用xx软件进行数据分析。

研究发现冠心病患者ANGPTL2启动子区甲基化水平较对照组(P50: 8.25% [P25: 5.46% P75: 17.98%] P = 0.001)相对较低(P50: 7.67% [P25: 6.22% P75: 10.43%]),表明ANGPTL2启动子甲基化与冠心病之间存在关联(OR: 0.890;95%置信区间,校正后的P = 0.001)。性别分析表明,ANGPTL2启动子甲基化与女性冠心病相关(调整P = 0.002),而与男性冠心病无关(调整P = 0.404)。我们发现基因甲基化与其他临床特征没有相关性。

本研究提供证据支持ANGPTL2启动子DNA甲基化状态与女性冠心病风险之间的关联。我们的数据表明,在女性中,ANGPTL2基因启动子DNA低甲基化与冠心病风险增加有关。

原始出处:

Jianqing Zhou, Li Chen ,Preliminary study of the relationship between promoter methylation of the ANGPTL2 gene and coronary heart disease

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=380525, encodeId=976738052566, content=冠脉夹层的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Mar 15 18:09:24 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994000, encodeId=16231994000ec, content=<a href='/topic/show?id=bbb039310b2' target=_blank style='color:#2F92EE;'>#启动子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39310, encryptionId=bbb039310b2, topicName=启动子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Dec 23 08:37:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369797, encodeId=ecc2369e97c7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Wed Jul 17 03:01:30 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369754, encodeId=4ed9369e544a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:23:02 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2020-03-15 jyzxjiangqin

    冠脉夹层的治疗。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=380525, encodeId=976738052566, content=冠脉夹层的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Mar 15 18:09:24 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994000, encodeId=16231994000ec, content=<a href='/topic/show?id=bbb039310b2' target=_blank style='color:#2F92EE;'>#启动子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39310, encryptionId=bbb039310b2, topicName=启动子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Dec 23 08:37:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369797, encodeId=ecc2369e97c7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Wed Jul 17 03:01:30 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369754, encodeId=4ed9369e544a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:23:02 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=380525, encodeId=976738052566, content=冠脉夹层的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Mar 15 18:09:24 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994000, encodeId=16231994000ec, content=<a href='/topic/show?id=bbb039310b2' target=_blank style='color:#2F92EE;'>#启动子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39310, encryptionId=bbb039310b2, topicName=启动子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Dec 23 08:37:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369797, encodeId=ecc2369e97c7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Wed Jul 17 03:01:30 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369754, encodeId=4ed9369e544a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:23:02 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=380525, encodeId=976738052566, content=冠脉夹层的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Mar 15 18:09:24 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994000, encodeId=16231994000ec, content=<a href='/topic/show?id=bbb039310b2' target=_blank style='color:#2F92EE;'>#启动子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39310, encryptionId=bbb039310b2, topicName=启动子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Dec 23 08:37:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369797, encodeId=ecc2369e97c7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Wed Jul 17 03:01:30 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369754, encodeId=4ed9369e544a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Jul 16 09:23:02 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 phoebeyan520

    学习了

    0

相关资讯

J Natl Cancer I:基于DNA甲基化的生物年龄是乳腺癌风险的重要预测因子!

近日,来自美国国家卫生研究院的科学家在线发表了一篇文章指出:基于DNA甲基化的生物年龄测量可能是乳腺癌风险重要的预测因子。

Blood:PRMT1介导FLT3甲基化促进FLT3-ITD+AML细胞存活维持

中心点:PRMT1通过甲基化FLT3蛋白的第972位和973位精氨酸残基,促进FLT3-ITD+ AML细胞的存活和生长。PRMT1抑制可通过FLT3 TKI治疗增强FLT3-ITD+AML细胞的清除。摘要:急性髓系白血病(AML)患者FLT3-ITD突变与其临床预后不良相关。虽然FLT3酪氨酸激酶抑制剂(TKIs)可有效消融激酶,但不能消除原始性FLT3-ITD+白血病细胞,这可能是白血病复发的

Allergy:青少年中关于DNA甲基化和过敏性敏感的基因组纵向研究

过敏性敏感的存在对儿童常见的哮喘和鼻炎的发展具有重要的影响。过敏性敏感的病因仍旧不清楚,并且其潜在的机制还没有建立。一些研究表明一些CpGs的DNA甲基化(DNAm)与过敏性敏感相关。然而,尚没有研究关注青少年时期。最近,有研究人员使用线性混合模型评估了青春期前后全基因组DNAm与室内、室外和食物过敏原过敏敏感之间相关性。研究发现,通过线性混合模型,鉴定了35个CpGs与过敏性敏感相关(错误发现率

Exp Physiol:卵清蛋白诱导的过敏性鼻炎中的MiR-199-3p/Dnmt3a/STAT3信号通路研究

之前的研究阐释了表观遗传修饰在过敏性鼻炎(AR)中的作用,尤其是DNA甲基化。然而,详细的机制仍旧不清楚。最近,有研究人员利用卵清蛋白诱导的AR小鼠探索了上述详细机制,并且利用行为评分、组胺和其他炎症因子来确定建模是否成功。另外,还利用实时定量、蛋白免疫印迹和亚硫酸氢盐测序PCR(BSP)的双报告子试验检测了相关基因和蛋白的表达、甲基化情况和靶标情况。研究发现,行为评分和分子标记均表明建模成功。D

AGING CELL:男性Y染色体年龄依赖性DNA甲基化模式

衰老相关表型和死亡率的性别差异可能表明,性染色体在衰老过程中起着关键作用。

Oncogene:动态m6A mRNA甲基化阐释了METTL3-m6A-CDCP1信号轴在化学致癌中的作用

N6甲基腺苷(m6A)是哺乳动物mRNAs中最丰富的内在修饰。尽管在各种各样的生理过程中具有重要的功能,m6A在化学致癌中的作用仍旧未知。最近,有研究人员分析了化学致癌剂诱导细胞性状转化过程中动态m6A mRNA修饰过程情况,并鉴定了细胞转化相关的受调控的m6A位点。明显的是,研究人员在恶性转化细胞CDCP1致癌基因的mRNA 3′-UTR区域发现m6A增加。m6A甲基转移酶METTL3和脱甲基酶